Why Gilead Sciences Is Poised to Keep Poppin'

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotech giant Gilead Sciences (NASDAQ: GILD  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Gilead, and see what CAPS investors are saying about the stock right now.

Gilead facts

 

 

Headquarters (founded)

Foster City, Calif. (1987)

Market Cap

$85.1 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$10.0 billion

Management

Chairman/CEO John Martin

President/COO John Milligan

Return on Equity (average, past 3 years)

36.5%

Cash/Debt

$1.9 billion / $8.0 billion

Competitors

Bristol-Myers Squibb 

GlaxoSmithKline

Pfizer 

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 97% of the 2,253 members who have rated Gilead believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, TMFTailwind, succinctly summed up the Gilead bull case for our community:

Very profitable company, and I expect [Gilead's] streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.

If you want market-thumping returns, you need to put together the best portfolio you can. Of course, despite a strong four-star rating, Gilead may not be your top choice.

We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2013." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.


Read/Post Comments (2) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On June 01, 2013, at 11:52 AM, TMFBlacknGold wrote:

    No patent expiration until 2018 and the drug to replace it (Stribild) is a 4-in-1 drug that's already on the market and contains the drugs losing exclusivity. Peak sales expected to be near $5 billion. Boom!

    --Maxxwell

  • Report this Comment On June 02, 2013, at 1:47 AM, mondaymedia wrote:

    I am currently in a 24 week trial of Gilead's new Hep C drug combination Sofosbuvir/GS-5885, without interferon or Ribavirin, under the guidance of a major hospital.

    [note: I asked if I was under any terms of confidentiality, and was told that I could talk about my results - much to my surprise]

    I have been through several Hep C drug trials over the last 10 years, but always with negative results.

    In all of the previous studies I participated in I had to take interferon and Ribavirin which produced horrific side effects - like I was coming down with a bad flu all day, every day. It slowly lowered the viral load, over the course of 8 weeks or so, but it never went to zero.

    In this current trial, my viral load went like this:

    Prior to trial - 6 million

    Week 1 - 153

    Week 2 - 35

    Week 3 - 0

    It's been zero ever since, AND, with virtually no side effects.

    I think I'm in the 14th week now, and will continue for a total of 24 weeks. I was told that those with lower viral loads went to zero in the first week.

    In previous trials the failure to achieve Sustained Viral Response (where the virus was cleared, but re-emerged after they stop taking the drugs) is thought to be caused by the virus "hiding" in scar tissue in the liver, that the blood-borne drugs can't reach.

    To me, if this proves true, it would indicate that all patients facing liver transplant should be given this drug before the operation. Otherwise, the blood borne virus will re-infect the new liver.

    I bought the stock as soon as my viral load went to zero - at around $40 per share.

    I'm thinking about buying more.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2464035, ~/Articles/ArticleHandler.aspx, 10/25/2014 9:09:38 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement